Li Li, Ren Qian, Sun Zhaohui, Yu Hua
Li Li, Department of Ophthalmology, Shijiazhuang People's Hospital, Shijiazhuang, 050011, Hebei, China.
Qian Ren, Department of Ophthalmology, Shijiazhuang People's Hospital, Shijiazhuang, 050011, Hebei, China.
Pak J Med Sci. 2022 May-Jun;38(5):1366-1370. doi: 10.12669/pjms.38.5.5231.
To observe the clinical efficacy and complications of conbercept combined with a 577-nm micropulse laser in patients with macular edema (ME) secondary to non-ischemic central retinal vein occlusion (CRVO).
A total of 153 patients who were diagnosed with non-ischemic CRVO-induced ME and treated by Shijiazhuang People's Hospital during January 2019 and January 2021 were included in this study. The patients were divided into a control group and an experimental group by choice of treatment. The control group was treated by conbercept alone, while the experimental group underwent laser treatment on this basis. The best corrected visual acuity (BCVA) was determined by the internationally standardized logarithm of the minimum angle of resolution (logMAR) chart and the central macular thickness (CMT) was measured by optical coherence tomography (OCT) before and at one and three months after treatment. Complications such as conjunctival hemorrhage and elevated intraocular pressure (if any) were recorded during the 3-month follow-up period.
Conbercept could improve the BCVA and CMT of patients with non-ischemic CRVO (P <0.05, respectively), and the combined use of conbercept with micropulse laser treatment yielded greater improvements in these measures compared with the pre-treatment condition (P <0.05, respectively); moreover, the differences between the control group and the experimental group were statistically significant (all P <0.05). The two groups had similar complication rates and did not record any serious adverse reactions.
Conbercept combined with 577-nm micropulse laser treatment can benefit patients with non-ischemic CRVO-induced ME by improving their visual acuity and relieve ME symptoms. As a regimen of impressive clinical efficacy, it is of great value for wide application in clinical practice.
观察康柏西普联合577纳米微脉冲激光治疗非缺血性中央视网膜静脉阻塞（CRVO）继发黄斑水肿（ME）患者的临床疗效及并发症。
纳入2019年1月至2021年1月在石家庄市人民医院诊断为非缺血性CRVO所致ME并接受治疗的153例患者。根据治疗选择将患者分为对照组和实验组。对照组仅接受康柏西普治疗，而实验组在此基础上进行激光治疗。治疗前、治疗后1个月和3个月，通过国际标准化的最小分辨角对数（logMAR）视力表测定最佳矫正视力（BCVA），并通过光学相干断层扫描（OCT）测量中心黄斑厚度（CMT）。在3个月的随访期内记录结膜出血和眼压升高（如有）等并发症。
康柏西普可改善非缺血性CRVO患者的BCVA和CMT（分别为P<0.05），与治疗前相比，康柏西普联合微脉冲激光治疗在这些指标上有更大改善（分别为P<0.05）；此外，对照组和实验组之间差异有统计学意义（均P<0.05）。两组并发症发生率相似，未记录到任何严重不良反应。
康柏西普联合577纳米微脉冲激光治疗可改善非缺血性CRVO所致ME患者的视力，缓解ME症状，对患者有益。作为一种临床疗效显著的治疗方案，在临床实践中广泛应用具有重要价值。
